Q2 2024 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2024-08-14 · accession 0001104659-24-089606
$7.83B
Reported value
95
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45337C102 | INCY | Incyte Corporation | $1.86B | 23.8% | 30,738,524 | Common | SOLE |
| 07725L102 | ONC | BeiGene, Ltd. | $1.51B | 19.3% | 10,568,897 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $696.8M | 8.90% | 42,877,916 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $553.2M | 7.07% | 1,974,590 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $293.8M | 3.75% | 7,569,090 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $262.7M | 3.36% | 6,398,365 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $239.6M | 3.06% | 3,576,038 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $190.3M | 2.43% | 9,399,960 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $181.1M | 2.31% | 23,222,222 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $179.0M | 2.29% | 5,995,928 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $105.2M | 1.34% | 5,840,059 | Common | SOLE |
| G01767105 | ALKS | Alkermes plc | $100.8M | 1.29% | 4,181,751 | Common | SOLE |
| 457669AB5 | INSM 0.75 06/01/28 | Insmed Incorporated | $90.4M | 1.16% | 42,850,000 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $90.4M | 1.16% | 10,045,336 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $86.6M | 1.11% | 3,731,695 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $81.5M | 1.04% | 27,525,640 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $81.0M | 1.04% | 3,882,125 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $74.9M | 0.96% | 6,443,398 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $69.3M | 0.89% | 4,865,819 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $60.3M | 0.77% | 1,466,547 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $59.0M | 0.75% | 4,368,443 | Common | SOLE |
| 457669AA7 | — | Insmed Incorporated | $56.2M | 0.72% | 32,887,000 | Common | SOLE |
| G52694109 | KNSA | Kiniksa Pharmaceuticals International, plc | $52.6M | 0.67% | 2,818,323 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $51.4M | 0.66% | 1,515,318 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $48.1M | 0.61% | 111,904 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $40.7M | 0.52% | 17,310,490 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $38.7M | 0.50% | 993,679 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $38.6M | 0.49% | 10,123,824 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $37.3M | 0.48% | 1,062,123 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $34.3M | 0.44% | 19,477,339 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $32.2M | 0.41% | 5,434,399 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $31.2M | 0.40% | 169,934 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $30.7M | 0.39% | 1,874,978 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $29.6M | 0.38% | 2,798,716 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $28.1M | 0.36% | 4,090,316 | Common | SOLE |
| 15678U128 | CERE1EUR | Cerevel Therapeutics Holdings, Inc. | $28.0M | 0.36% | 683,588 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $25.7M | 0.33% | 1,097,082 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $23.7M | 0.30% | 672,096 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $20.8M | 0.27% | 1,562,500 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $18.4M | 0.23% | 4,916,095 | Common | SOLE |
| N5749R100 | 2GH | Merus N.V. | $17.8M | 0.23% | 300,000 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $16.6M | 0.21% | 456,015 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $16.3M | 0.21% | 2,784,792 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $13.0M | 0.17% | 2,380,949 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $12.3M | 0.16% | 464,718 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $10.3M | 0.13% | 545,431 | Common | SOLE |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $10.2M | 0.13% | 1,034,600 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $9.8M | 0.13% | 2,997,772 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $9.6M | 0.12% | 2,497,526 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $9.5M | 0.12% | 2,108,949 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $9.2M | 0.12% | 247,644 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $9.0M | 0.11% | 4,004,756 | Common | SOLE |
| 04746L104 | — | Athira Pharma, Inc. | $8.4M | 0.11% | 3,153,807 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $8.3M | 0.11% | 1,691,530 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $7.6M | 0.10% | 1,160,117 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $6.5M | 0.08% | 190,476 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics, Inc. | $6.4M | 0.08% | 750,000 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $6.3M | 0.08% | 891,335 | Common | SOLE |
| 23306J200 | — | DBV Technologies S.A. | $5.9M | 0.07% | 7,307,131 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $5.7M | 0.07% | 1,695,294 | Common | SOLE |
| 21217B100 | CTNM | Contineum Therapeutics, Inc. | $5.5M | 0.07% | 312,500 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines, Inc. | $5.4M | 0.07% | 131,533 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $5.4M | 0.07% | 100,000 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $5.3M | 0.07% | 1,028,466 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $5.0M | 0.06% | 549,212 | Common | SOLE |
| 43906K209 | HOOK | HOOKIPA Pharma Inc. | $4.8M | 0.06% | 8,128,151 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $4.7M | 0.06% | 1,381,898 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals, Inc. | $4.7M | 0.06% | 103,927 | Common | SOLE |
| 87424L207 | TLIS | Talis Biomedical Corporation | $4.4M | 0.06% | 508,323 | Common | SOLE |
| 014442107 | ALEC | Alector, Inc. | $4.2M | 0.05% | 927,264 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $4.2M | 0.05% | 2,173,622 | Common | SOLE |
| 83086J200 | SKYE | Skye Bioscience, Inc. | $4.0M | 0.05% | 500,000 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $3.7M | 0.05% | 48,885 | Common | SOLE |
| 03969T109 | ARCT | Arcturus Therapeutics Holdings Inc. | $3.7M | 0.05% | 151,329 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio Co. | $3.4M | 0.04% | 1,206,957 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $2.7M | 0.03% | 114,833 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $2.3M | 0.03% | 1,172,175 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $2.3M | 0.03% | 2,343,695 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $2.2M | 0.03% | 1,086,115 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $2.0M | 0.03% | 797,460 | Common | SOLE |
| N62509109 | NAMS | NewAmsterdam Pharma Company N.V. | $1.9M | 0.02% | 96,827 | Common | SOLE |
| 78667J108 | SG7 | Sage Therapeutics, Inc. | $1.9M | 0.02% | 171,026 | Common | SOLE |
| 918385204 | VTVT | vTv Therapeutics, Inc. | $1.7M | 0.02% | 97,314 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $1.6M | 0.02% | 1,557,630 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $1.1M | 0.01% | 536,832 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $1.0M | 0.01% | 628,939 | Common | SOLE |
| 717081103 | PFE | Pfizer Inc. | $979,300 | 0.01% | 35,000 | Common | SOLE |
| 00449L102 | 698 | Achilles Therapeutics plc | $903,645 | 0.01% | 1,108,767 | Common | SOLE |
| 01626L105 | — | Aligos Therapeutics, Inc. | $726,740 | 0.01% | 2,076,400 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $521,679 | 0.01% | 322,024 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals, Inc. | $468,308 | 0.01% | 75,778 | Common | SOLE |
| 004890109 | ACRV | Acrivon Therapeutics, Inc. | $306,733 | 0.00% | 52,885 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $258,905 | 0.00% | 45,027 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $169,606 | 0.00% | 10,607 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $13,833 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.